With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

Recent medical research reveals striking differences between surgical and pharmaceutical approaches ... show improved ...

As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

GLP-1 weight-loss users shift their spending on food purchases both in and out of home. At grocery retail, they are spending more on foods that support GLP-1 balance, including vegetables, eggs and ...

Ozempic and Wegovy are two popular injectable medications for weight loss and diabetes. But what’s the difference?

Higher-income households with at least one user of GLP-1 class of weight loss drugs cut their grocery spending by nearly 9%, ...

so when a class of drugs makes it possible to lose weight and keep it off, it’s a welcome and helpful development. Though we are now seeing several new iterations of the class of drugs known ...